Abstract:Type I interferons (IFNs) play essential roles in establishing and modulating host defense against microbial infection via induction of IFN-stimulated genes (ISGs) through Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway. However, dysregulation of IFNs production and function could also mediate immune pathogenesis such as inflammatory autoimmune diseases and infectious diseases via aberrantly activating inflammatory responses or improperly suppressing microbial controls. Thus, IFN responses need to be tightly regulated to achieve protective immunity against microbial infection while avoiding harmful toxicity caused by improper or prolonged IFN signaling. Multiple levels of cellular and molecular events act in a cooperated manner to regulate IFN responses, in especial, post-translational modification (PTMs) of signaling molecules and epigenetic modification of gene expression programs are two important mechanisms for regulation of IFN signaling and thus critical for orchestrating IFN-mediated host immune response to the complex pathogenic or environmental stimuli. Conventional PTMs such as phosphorylation and polyubiquitylation, as well as numerous other PTMs including acetylation, ISGylation, SUMOylation and methylation have been shown to potently modulate type I IFN signaling transduction via targeting distinct signaling steps or components. Moreover, epigenetic mechanisms, such as histone modification, DNA methylation, non-coding RNAs play critical roles in regulating chromatin structure and function, leading to flexible and dynamic gene expression patterns downstream type I IFN signaling. Herein, we summarize the recent advances in the PTMs and epigenetic mechanisms in regulation of type I IFN signaling and responses. The involvement of dysregulated IFN signaling in inflammatory and autoimmune diseases are also discussed.

The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases

Type I Interferons in the Pathogenesis and Treatment of Sjögren’s Syndrome: an Update

Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options

Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice

Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?

Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics

The role of innate lymphoid cells in inlfammatory dermatosis

Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment

Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis

The Protective Role of Type I Interferons in the Gastrointestinal Tract

Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis

The crucial regulatory role of type I interferon in inflammatory diseases

Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells

IRF/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease

Type I Immune Response Induces Keratinocyte Necroptosis and is Associated with Interface Dermatitis.

Insight into the role of IRF7 in skin and connective tissue diseases

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus

An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation

From IL-17 to IFN-γ in inflammatory skin disorders: Is transdifferentiation a potential treatment target?